Guild Learning and Development is partnering with Gilead Sciences in an online course
The course is titled Management of Hepatitis C and the role of pharmacy.
Hepatitis C (HCV), a blood-borne virus which primarily affects the liver, is detectable in 0.9% of the Australian population.
While there is no vaccine to prevent hepatitis C, advances in treatment of the condition have progressed significantly in the past couple of years with the use of direct acting antiviral medications resulting in cure rates greater than 90 per cent.
This course examines the pathophysiology of HCV and the availability of new direct acting antivirals to treat the disease.
This course will also discuss the role pharmacists can play in supporting patients with chronic HCV through the provision of advice on screening, treatment, risk reduction and treatment compliance.
Community pharmacist and Victorian Branch President of the Pharmacy Guild of Australia, Anthony Tassone, said advances in treatment options for patients with hepatitis C were having a significant impact on their lives.
“One of the most important roles pharmacists can play in the management of HCV is to educate patients about the importance of remaining adherent to the prescribed treatment as this is critical to its success in therapy,” he said.
This activity has been accredited for 0.75 hours of Group 1 CPD (or 0.75 CPD credits), suitable for inclusion in an individual pharmacist’s CPD plan, which can be converted to 0.75 hours of Group 2 CPD (or 1.5 CPD credits) upon successful completion of relevant assessment activities.
Guild Learning and Development has thanked Gilead Sciences, manufacturers of Harvoni, Sovaldi and Epclusa for their financial support and input of expertise in the development of this course.
Gilead product information is available from Gilead Medical Information.